Table 7.
Effects of Hiltonol® on various lung parameters of C57BL/6J mice and TLR-4 -/- mice infected with a lethal dose of mouse-adapted SARS-CoV.
| Treatment | Virus titers (Log10 CCID50/g) ± SD | Visual lung scores ± SD | Lung weights (g) ± SD |
|---|---|---|---|
| Day 3 | |||
| PSS in C57BL/6J mice | 5.06 ± 0.55 | 0.0 ± 0.0 | 0.18 ± 0.00 |
| Hiltonol® (1 mg/kg/) in C57BL/6J mice | 2.06 ± 0.38*** | 0.0 ± 0.0 | 0.22 ± 0.01 |
| PSS in C57BL/6J/10ScNJ TLR-4 -/- mice | 5.00 ± 0.29 | 0.0 ± 0.0 | 0.20 ± 0.02 |
| Hiltonol® (1 mg/kg/) in C57BL/6J/10ScNJ TLR-4 -/- mice | 1.81 ± 0.31*** | 0.0 ± 0.0 | 0.23 ± 0.21 |
| Day 6 | |||
| PSS in C57BL/6J mice | 3.44 ± 0.24 | 0.0 ± 0.0 | 0.17 ± 0.01 |
| Hiltonol® (1 mg/kg/) in C57BL/6J mice | 2.06 ± 0.66*** | 0.0 ± 0.0 | 0.20 ± 0.01 |
| PSS in C57BL/6J/10ScNJ TLR-4 -/- mice | 2.63 ± 0.43 | 0.0 ± 0.0 | 0.17 ± 0.01 |
| Hiltonol® (1 mg/kg/) in C57BL/6J/10ScNJ TLR-4 -/- mice | 1.50 ± 0.00*** | 0.0 ± 0.0 | 0.20 ± 0.01 |
***p < 0.001 versus PSS control.